PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLext2)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
PregLem SA
ClinicalTrials.gov Identifier:
NCT01642472
First received: July 10, 2012
Last updated: March 18, 2013
Last verified: March 2013
  Purpose

This is a phase III, multicentre, long-term open-label extension of the phase III study: Pearl IIIextension (PGL09-027). During Pearl III (PGL09-026) and subsequent Pearl III extension (PGL09-027), patients have been exposed to a total of 4 cycles of daily 3month open-label treatment with ulipristal acetate 10mg before entering the proposed study Pearl extension 2 (PGL11-024).

This proposed study consists of 4 further consecutive courses of 3 months (84 days) open label ulipristal acetate 10mg once daily treatment each separated by a drug free period.


Condition Intervention Phase
Uterine Fibroids
Drug: Ulipristal acetate - open label
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding

Resource links provided by NLM:


Further study details as provided by PregLem SA:

Primary Outcome Measures:
  • Myoma symptom control assessed with a Global Study Treatment Satisfaction Questionnaire [ Time Frame: After 18 months. ] [ Designated as safety issue: No ]
    Average score of the first 3 questions.


Estimated Enrollment: 90
Study Start Date: July 2012
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PGL4001 Drug: Ulipristal acetate - open label
PGL4001 tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject completed visit F - Follow-up of Pearl III extension study (PGL09-027) - without significant deviations.
  • Females of childbearing potential are advised to practice a non-hormonal method of contraception.

Exclusion Criteria:

  • Subject has a history of uterus surgery (e.g. hysterectomy, myomectomy) or uterine artery embolization in Pearl III extension (PGL09-027) or afterwards that would interfere with the study assessments.
  • Subject has taken or is likely to require treatment during the study with drugs that are not permitted by the study protocol.
  • Subject is lactating, has a positive pregnancy test at study start or is planning a pregnancy during the course of the study.
  • Subject has abnormal baseline findings, any other medical condition(s) or laboratory finding that, in the opinion of the investigator, might jeopardise the subject's safety or interfere with study evaluations.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01642472

Locations
Austria
Medical University Vienna
Vienna, Austria, 1090
Belgium
Cliniques Universitaires Saint-Luc, Gynécologie-Obstétrique,
Brussels, Belgium, 1200
CHR de la Citadelle
Liège, Belgium, 4000
Cliniques Universitaires UCL de Mont-Godinne
Yvoir, Belgium, 5530
Poland
Prywatna Klinika Polozniczo-Ginekologiczna
Bialystok, Poland, 15-224
INVICTA Sp. Z o.o.
Gdańsk, Poland, 80-895
Private practice
Katowice, Poland, 40-724
Prywatny Gabinet Lekarski Ginekologia I Poloznictwo Ultrasonografia
Lodz, Poland, 90-602
Specjalistyczny Gabinet Ginekologiczno-Polozniczy
Lublin, Poland, 20-064
Gabinet Lekarski Specjalistyczny "Sonus"
Warszawa, Poland, 02-066
Centralny Szpital Kliniczny MSWiA w Warszawie, Klinika Poloznictwa, Chorob Kobiecych i Ginekologii Onkologicznej
Warszawa, Poland, 02-507
Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, I Katedra i Klinika Ginekologii i Położnictwa
Wroclaw, Poland, 50-369
Spain
Hospital Universitario Vall Hebrón (Gynecology department) Edificio Maternal
Barcelona, Spain, 08035
Clinica Ginecologica CEOGA
Lugo, Spain, 27002
Private Practice
Madrid, Spain, 28009
HOSPITAL Universitario 12 de Octubre y Fundación de Investigación Biomédica Hospital 12 de Octubre
Madrid, Spain, 28041
Sponsors and Collaborators
PregLem SA
  More Information

No publications provided

Responsible Party: PregLem SA
ClinicalTrials.gov Identifier: NCT01642472     History of Changes
Other Study ID Numbers: PGL11-024
Study First Received: July 10, 2012
Last Updated: March 18, 2013
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
Poland: Ministry of Health
Austria: Federal Office for Safety in Health Care
Spain: Agencia Española de Medicamentos y Productos Sanitarios

Additional relevant MeSH terms:
Leiomyoma
Myofibroma
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Connective Tissue
Connective Tissue Diseases

ClinicalTrials.gov processed this record on October 19, 2014